<DOC>
	<DOCNO>NCT00513058</DOCNO>
	<brief_summary>RATIONALE : Lapatinib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , vinorelbine , work different way stop growth tumor cell , either kill cell stop divide . Giving lapatinib together vinorelbine may kill tumor cell . PURPOSE : This phase I trial study side effect best dose lapatinib vinorelbine treat woman HER2-overexpressing locally advance metastatic breast cancer .</brief_summary>
	<brief_title>Lapatinib Vinorelbine Treating Women With HER2-Overexpressing Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate tolerability feasibility lapatinib ditosylate vinorelbine ditartrate combination determine maximum tolerate dose vinorelbine ditartrate combination biologically active dose lapatinib ditosylate . Secondary - Determine maximum administer dose . - Investigate pharmacokinetic interaction relate combination vinorelbine ditartrate lapatinib ditosylate . - Determine toxicity vinorelbine ditartrate lapatinib ditosylate . - Determine objective response rate patient measurable lesion . - Validate safety efficacy oral vinorelbine ditartrate lapatinib ditosylate combination , accord vinorelbine ditartrate oral/IV dose equivalence . OUTLINE : This multicenter , dose-escalation study . Patients receive oral lapatinib ditosylate day -7 21 course 1 day 1-21 course . Patients also receive vinorelbine ditartrate IV 15 minute day 1 8 . Courses repeat every 21 day 12 month absence disease progression unacceptable toxicity . Cohorts 3-9 patient receive escalate dos lapatinib ditosylate vinorelbine ditartrate maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 9 patient experience dose-limiting toxicity course 1 . Once MTD determine oral lapatinib ditosylate IV vinorelbine ditartrate , additional cohort 9 patient receive oral vinorelbine ditartrate oral lapatinib ditosylate .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced breast cancer ( metastatic locally advance ) Tumor overexpressing HER2 ( HER2 3+ IHC OR HER2 2+ IHC FISH positive ) sample primary and/or secondary tumor Measurable evaluable disease Cancer progressive treatment least 1 line , , 2 line , chemotherapy include trastuzumab ( Herceptin® ) Patients present treat asymptomatic cerebral metastasis leptomeningeal metastasis may include neurologically stable received steroid anticonvulsant treatment least 4 week study entry PATIENT CHARACTERISTICS : Inclusion criterion : Female Menopausal status specify Patients must estimate survival least 3 month WHO performance status ( ECOG ) 02 Hemoglobin ≥ 9 g/dL ANC ≥ 1,500/mm³ Platelets ≥ 100,000/mm³ Total bilirubin ≤ 2.5 mg/dL ALT AST ≤ 3 time upper limit normal Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 40 mL/min LVEF ≥ 50 % ( echographic isotopic method ) Potentially reproductive patient must agree use effective contraceptive method study treatment Patients must affiliate Social Security system Exclusion criterion : Uncontrolled cardiac pathology Dysphagia inability swallow vinorelbine ditartrate soft capsule Malabsorption syndrome disease significantly affect gastrointestinal function Preexisting neuropathy ( grade ≥ 2 ) Pregnant woman , woman likely become pregnant , woman breastfeed Any psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule Individuals deprive liberty Exclusion criterion : Prior major resection stomach proximal bowel could affect absorption oral drug Prior vinorelbine</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>advanced breast cancer</keyword>
</DOC>